The article cites both the growth in federal merger-objection lawsuits, which challenge M&A deals on grounds that the company's board of directors breached their fiduciary duties, as well as the recent shift in the filing of securities class actions from state court to federal court as major contributing factors in the recent uptick in SCA filings, and also note that certain industries—particularly companies in the fields of biotechnology, pharmaceuticals, and healthcare, may be targeted at a higher rate.